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Abstract 
 
Mutations in the α-synuclein encoding gene, SNCA, have been implicated in the 
pathophysiology and progression of Parkinson’s disease, a neurodegenerative disorder 
which results in motor and cognitive abnormalities in patients. Missense mutations, 
duplications and triplications of the gene relate to the onset and advancement of the ailment, 
but the role of α-synuclein protein in the pathogenesis is incompletely understood. Recent 
investigation of the disease and its other associated proteins has driven interest in the role of 
mitochondrial abnormalities in Parkinson’s disease.  Through use of an ecdysone-inducible 
expression system in the mammalian neuronal cell line, 1RB3AN27, the detrimental effects of 
mutant A53T α-synuclein upon mitochondrial morphology has been established, which 
corroborates the work of similar studies. Complementary immunocytochemistry and western 
blot analyses allude to the time dependent increase in protein expression and the 
corresponding fragmentation of mitochondria. Analysis of mitochondrial function using 
Seahorse XFe24 technology proved inconclusive; further work is needed to confirm the 
consequences of mutant A53T α-synuclein expression upon mitochondrial respiratory 
capacity in this disease model. 
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Introduction 
Parkinson’s disease is a common neurological disorder, characterised by the 
degeneration of the nigrostriatal dopaminergic pathway, which affects more than 
100,000 individuals in the UK alone (Campenhausen et al, 2005). As the principle 
neurotransmitter of the extrapyramidal system, dopamine plays a major role in the 
regulation and control of motor nuclei and their associated pathways (Marieb and 
Hoene, 2010). Deterioration of dopaminergic neurons in the substantia nigra results 
in the clinically recognisable triad of Parkinson’s symptoms; rigidity, resting tremor 
and bradykinesia (Siegel et al, 2006). 
The aetiology of Parkinson’s disease is still unknown, although both genetic 
and environmental factors have been implicated, it is thought to be a polygenic 
disease with various causal interactions. Through research into cases of familial 
Parkinson’s, multiple gene mutations have been identified, some of which have been 
shown to adversely affect mitochondrial function (Klein and Westernberger, 2012). 
Abnormalities of mitochondria have been pathogenically associated with Parkinson’s 
disease since the discovery of human parkinsonism as a result of self-administered 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-contaminated synthetic  
meperidine in 1982 (Langston et al, 1983).  MPTP is a mitochondrial toxicant, the 
oxidised form of which, MPP+, acts by inhibiting complex 1 of the mitochondrial 
transport chain, thus impeding energy production which results in abnormal neuronal 
function (Dauer and Przedborski. 2003).  
Parkinson’s disease occurs in both sporadic and familial forms throughout the 
population, and much work has been undertaken to identify genetic factors which 
cause the disease or contribute to an individual’s susceptibility. Whist fewer than 
10% of cases are thought to be familial (Ibánez et al, 2009), research has provided 
evidence of genetic factors which play a role in these cases and also in sporadic 
Parkinson’s (Klein and Westernberger, 2012). Both autosomal dominant and 
recessive genes have been identified to contribute to the pathology, and four in 
particular have been widely investigated to elucidate their role; SNCA, PINK1, Parkin 
and LRRK2. The SNCA gene encodes for α-synuclein protein, and its mechanistic 
effects within Parkinson’s disease are not yet understood, however investigations of 
the other genes has provided a clearer idea of how genetic and environmental 
interactions may affect the disease and contribute towards its progression. Both 
Parkin and LRRK2 genes play a role in major intracellular waste disposal systems; 
Parkin in the ubiquitin-proteasome system, and LRRK2 in the autophagy-lysosome 
pathway (Schnabel, 2010). When functional, they may offer protection against other 
pathological contributors, through degradation and removal of proteins. Evidence 
indicates that PINK1 directly recruits Parkin from the cytosol to mitochondria, where 
it becomes metabolically active; their function in a common pathway infers that 
defects in one will therefore affect the other, leading to the common pathology 
(Stephanis, 2012; Schnabel, 2010).  
The SNCA gene is of particular interest in Parkinson’s research (Klein and 
Westernberger, 2012; Polymeropoulos et al, 1998) as α-synuclein protein is found in 
both familial and sporadic cases of the disease (Stephanis, 2012). Whilst this 
aggregated protein is a distinctive pathological hallmark in Parkinson’s patients, in 
the form of Lewy bodies and Lewy neuritis which are found most often in the 
substantia nigra, its role in the disease remains undetermined (Siegel et al, 2006). 
Normal α-synuclein is usually found in synaptic vesicles and membranes, along 
axons and terminals in a variety of neurons (Stephanis, 2012). SNCA is a gene of 
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autosomal dominant inheritance and its mutated forms are often found in cases of 
early onset Parkinson’s (<50 years age of onset)(Klein and Westernberger, 2012). 
Several mutated forms of this gene have been linked to the diseases progression, 
including the A53T missense mutation, which was first identified in a large Italian-
Greek family, the Contursi kindred (Recchia, 2004). In this abnormal form, a G209A 
substitution occurs, which alters the amino acid sequence of the protein, causing a 
conformational aberration which leads to intracellular aggregation of α-synuclein.  
As mitochondrial abnormalities have been attributed to causing Parkinson-like 
symptoms, exampled by the MPTP case, investigations have been undertaken to 
determine whether the genetic mutations associated with Parkinson’s disease have 
affects upon these organelles. Knott et al (2008) explain the importance of 
mitochondria in enabling neurons to function; they are essential for energy 
production, Ca2+ regulation, transport processes, and the release and reuptake of 
neurotransmitters, such as dopamine, at synapses. Neurons have a high energy 
demand, and require a healthy population of mitochondria to supply them with ATP, 
as they are unable to switch to glycolysis if oxidative phosphorylation becomes 
limited. Mitochondrial defects are observable in various common neurodegenerative 
disorders; oxidative damage is an early event in Alzheimer’s disease and complex I 
inhibition by MPTP induces parkinsonism (Nunomura et al, 2001; Betarbet et al, 
2000; Fornai et al, 2005). The PINK1 gene, and its Parkinson’s disease associated 
mutations, was of substantial importance in establishing a genetic link between 
Parkinson’s disease and mitochondrial dysfunction; the identification of this genes 
mutation in patients provided the first evidence of a direct link between Parkinson’s 
disease and dysfunction of a mitochondrial protein (Valente et al, 2004). 
 Mitochondrial dynamics (see figure 1) play a critical role in maintaining a 
healthy population of functioning mitochondria within cells, especially when exposed 
to metabolic or environmental stresses. The term encompasses the organelles 
fission and fusion abilities, as well as their movement processes which allow them to 
supply energy to cellular extensions, such as axons and dendrites (Chen and Chan, 
2009; Xie and Cheng, 2012). Through fusion, the effects of stress can be mitigated 
by mixing the contents of partially damaged mitochondria to allow complementation 
of the undamaged parts in the combined organelle. Fission is the opposite of this 
process; it is required to divide mitochondria and to enable removal of those which 
are severely damaged, providing a quality control mechanism within the cell (Youle 
et al, 2012). Mitochondrial movement, fission and fusion are all controlled by proteins 
which interact with the organelles; Mfn1, Mfn2 and OPA1 are involved in fusion, Drp1 
and Fis1 have been show to play roles in fission, and it is thought that secondary 
roles of some fusion proteins facilitate mitochondrial movement throughout the cell 
(Chan, 2006; Knott et al, 2008; Mecusen et al, 2006).   
Recent studies have linked genetic mutations found in other forms of familial 
Parkinson’s disease to mitochondrial damage within the pathology (Cui et al, 2010; 
Knott et al, 2008; Sum et al, 2006; Valente et al, 2004; Wild and Dikic, 2010). 
Mutations in the PTEN-induced putative kinase 1 (PINK1) gene have been 
demonstrated to contribute to mitochondrial deficiencies and manipulation of 
mitochondrial dynamics has been shown to alleviate these effects (Cui et al, 2012; 
Sum et al, 2006; Valente, 2004). Valente et al (2004) performed an early 
investigation into the effects of a PINK1 mutant (G309D) on mitochondrial function in 
vitro, using monkey kidney COS-7 cells and SH-SY5Y neuroblastoma cells. 
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Their study demonstrated that both mutant and wild type PINK1 localised to 
the mitochondria, and found that under normal cellular conditions there was no 
significant difference in the basal respiratory capacity of the cells. Following stress, 
induced by treatment with MG-132, the PINK1 mutant cells displayed a significant 
decrease in respiration from that of normal. In this study, a fluorescence-activated 
cell sorting based assay was used to assess mitochondrial function. In a 2006 study 
by Sum et al, PINK1’s neuroprotective properties were demonstrated; Using SH-
SY5Y neuroblastoma cells, a loss of mitochondrial membrane potential in PINK1 
cells was shown when treated with neurotoxins, in comparison to normal SH-SY5Y 
cells. Overexpression of PINK1 followed by the same treatment demonstrated its 
protective effect as the loss of mitochondrial membrane potential was suppressed. 
Introduction of Parkinson’s disease-associated PINK1 mutations G386A and G409P 
in their model significantly reduced PINK1 kinase activity, providing some clues into 
the mechanism by which PINK1 is protective. The majority of PINK1 mutations affect 
catalytically critical regions of the protein, which alters its function and abolishes its 
neuro-protective effect. Cui et al (2010) demonstrate the effect of reduced 
mitochondrial fission in vitro, through transfection of N27 dopaminergic neurons 
expressing wild type or mutant PINK1 (L347P or W437X) with dominant negative 
Drp1K38A or treatment with mitochondrial division inhibitor (mdivi-1). High 
performance liquid chromatography measurement of ATP and morphological 
assessment of treated and non-treated cells revealed that both Drp1K38A and mdivi-1 
successfully attenuate the morphological and functional defects induced by PINK1 
overexpression. This earlier study in the Tieu lab shares similarities with our current 
project, so similar techniques will be utilised to elucidate the pathological effects of α-
synuclein in a cellular Parkinson’s disease model.  
Current treatment of Parkinson’s disease involves the administration of 
dopamine pre-cursors or agonists (Marieb and Hoene, 2010). Most commonly, 
Figure 1; A basic mitochondrial fission/fusion diagram. Fission is the process through 
which new mitochondria are produced, and quality of the organelles may be checked, by 
facilitating the removal of damage mitochondria from the cellular network for destruction 
by mitophagy. Drp1 and Fis1 are two proteins involved in mitochondrial fission. 
Mitochondrial fusion helps to mitigate the effects of mitochondrial damage as the 
combination of two damaged organelles is thought to facilitate a compensatory effect, 
allowing survival of the fused mitochondrion, Fusion of the inner and outer mitochondrial 
membrane is controlled by Mfn1, Mfn2 and OPA1. (Knott et al, 2008) 
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Levodopa (L-dopa) is given along with DOPA-decarboxylase inhibitors, which are 
unable to permeate the blood brain barrier, thus specifying L-DOPA conversion into 
dopamine to within the brain. This causes an increase in neural dopamine levels, 
reducing the symptomatic presentation of the disorder (Grayson, 2010). Another 
treatment method is the use of dopamine agonists, which imitate dopamine’s action 
within the brain (Smith, 2010). Whilst both of these treatments, along with several 
others, have proven effective at relieving the symptomatic presentation of 
Parkinson’s disease, there are not yet any neuro-restorative or neuro-protective 
treatments for the disorder. No therapeutic strategy has been devised to target the 
mechanisms of Parkinson’s disease; medicine can merely slow its progression. If 
science can further the understanding of what causes the pathophysiology of 
Parkinson’s, it can be targeted to try and combat the cause of the disease, and 
therefore work into the mechanisms is fundamentally important in furthering therapy 
development.  
The aim of this study was to characterise the toxicity of mutant α-synuclein 
(Parkinson’s disease-linked A53T missense mutation) on mitochondrial morphology 
and function in stably inducible dopaminergic N27 neuronal cells, using empty vector 
transfected cells as a comparative control. Characterisation of this cell model will aid 
future investigations, as well as demonstrating the mechanism of the disease, which 
may help in the development of prospective therapeutic methods.  
 
Materials and Methods 
 
Generation and culture of stable and inducible α-synuclein cell line 
The expression of wild type and mutant A53T α-synuclein in the dopaminergic 
1RB3AN27 (N27) neuronal cells was accomplished using The Complete Control
® 
Inducible Mammalian Expression System (Stratagene, La Jolla, CA) as previously 
Figure 2; Inducible overexpression of α-synuclein in rat dopaminergic N27 neuronal cells. 
Stable cells containing a vector that constitutively expressed the ecdysone receptor 
(VgEcR) and the retinoid X receptor (RXR) were generated. These cells were subsequently 
stably transfected with a second vector that contains the ecdysone-responsive element 
(E/GRE) and a multiple cloning site for the insertion of either human wild type α-synuclein, 
mutant A53T α-synuclein or an empty vector. The VgEcR-retinoid X receptor heterodimer 
binds to the E/GRE. In the presence of Ponasterone A, an ecdysone analogue inducer, the 
co-repressors are released from VgEcR, and co-activators are recruited resulting in gene 
activation via the minimal heat shock promoter (mHSP). IRES, internal ribosomal entry site. 
The Plymouth Student Scientist, 2015, 8, (1), 4-19 
 
[9] 
 
described in the Tieu lab (Cui et al, 2010)(see figure 2). Wild type and mutant A53T 
α-synuclein, and empty vector control cells were cultured in selective media specific 
for the transfected cells (RPMI medium containing 10% FBS, G418 [1:100] and 
Hygromycin B [1:250]), prior to induction of protein expression with Ponasterone A 
[1:100 dilution](Invitrogen™).  
 
Assessment of mitochondrial morphology 
Empty vector, wild type and A53T α-synuclein cells were grown on poly-L-lysine 
coated coverslips in 24 well plates. Following overnight growth to allow cell 
adjustment to growth on the coverslips, Ponasterone A [1:100 dilution](InvitrogenTM) 
was added to the media to induce protein expression. Multiple time points post-
induction were investigated for each cell line; 24 hours, 48 hours and 72 hours. 
Control groups for α-synuclein wild type, A53T mutant and empty vector were grown 
for the same time points without the presence of Ponasterone A in the media. After 
the appropriate growth period, cells were fixed with 4% paraformaldehyde in media, 
and immunocytochemistry performed. Mitochondria were labelled with polyclonal 
rabbit Tom20 antibody (Santa Cruz Biotechnology Inc.) and α-synuclein with 
monoclonal mouse antibody (BD Transduction Laboratories™). Coverslips were then 
mounted with Prolong Gold Antifade Reagent with DAPI (Invitrogen) and images 
captured using epifluorescence (Nikon 80i) and confocal microscopy. 
 
Analysis of mitochondrial function 
Empty vector and A53T α-synuclein cells were cultured in XFe24 micro-plates 
(Seahorse Bioscience) for 48 hours prior to induction of protein expression with 
Ponasterone A [1:100 dilution](Invitrogen™). Culture was continued for 24-48 hours 
post-induction before analysis of cellular respiration using an XFe24 Extracellular 
Flux Analyser (Seahorse Bioscience). Oligomycin, FCCP and a rotenone-antimycin 
mixture were injected sequentially to determine the respiratory capacity, coupling 
and non-mitochondrial function of the cells through measurement of their oxygen 
consumption rate (OCR). Seahorse technology avoids the use of labels which may 
modify cellular function to provide unaltered measurement of cellular respiratory 
capacity. Variable buffers were tested to determine the most effective protocol for the 
cell line used, in order to optimise the technique. The protocol used was adapted 
from that used by Affourtit’s lab to account for the differences in cellular demands 
and growth protocols (C Affourtit and J Barlow, 2012, unpublished). Raw data from 
these three experiments was converted into values of respiratory capacity, coupling 
and non-mitochondrial respiration in Excel, and their significance analysed using a 
two-way ANOVA. 
 
Western blot analysis of protein expression 
To complement immunocytochemistry data of protein effect upon mitochondria, 
western blot analysis was used to compare the levels of protein expression between 
wild type α-synuclein and empty vector cells with established controls at variable 
time points. Cells cultured in T25 flasks with RPMI, 10% FBS, G418 (1:100 dilution) 
and Hygromycin B (1:250) had protein expression induced by Ponasterone A [1:100 
dilution](Invitrogen™) addition for 6, 24, 48 or 72 hours. After the allotted growth 
period, cells were trypsinised, washed with PBS and centrifuged. Following removal 
of the supernatant, the cell pellets were frozen at -80oC until samples for all of the 
time points were obtained. Prior to western blot analysis of protein expression, a 
BCA assay (Pierce™, Thermo Scientific) determined the levels of protein in each 
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sample and these allowed calculation of the appropriate sample quantities to use in 
order to equalise the samples. The final western blots were run using a 15% 
resolving gel and a 4% stacking gel, with ten wells per gel. The protein ladder 
(Kaleidoscope, Biorad) and a positive control of recombinant α-synuclein were run in 
the first two wells, followed by the samples and further controls; α-synuclein 
expressing human brain sample served as another positive control. Gels ran for 90 
minutes at 80V and samples were transferred to nitrocellulose gel at 100V for 30 
minutes. Following probing with α-synuclein and β-actin antibodies, the gel was 
developed using ECL.  
 
Results 
 
Generation of stable cells with inducible expression of human wild type and 
mutant α-synuclein 
To facilitate characterisation of the role of α-synuclein in Parkinson’s disease, 
stable cells lines with inducible expression of wild-type or dominant mutant A53T 
α-synuclein and empty vector controls were created. A53T was selected as the 
mutant form for investigation as it has been reported to have the greatest effect 
upon mitochondrial function (Kamp et al, 2010).  Expression of the wild type and 
mutant A53T α-synuclein in the dopaminergic 1RB3AN27 (N27) neuronal cells was 
accomplished using The Complete Control® Inducible Mammalian Expression 
System (Stratagene, La Jolla, CA), chosen as these rat mesencephalic 
dopaminergic neuronal cells display tubular mitochondrial morphology, aiding the 
identification of abnormal, fragmented mitochondria. Wild type α-synuclein was 
used in investigation of morphology and time dependent protein expression, 
however it was discounted from functional investigations of mitochondria as the 
mutant form have previously been reported to produce the most profound 
functional effects. The empty vector controls have been through the same 
transfection process as the α-synuclein expressing cells, to account for any effects 
which the process may have upon cellular function. 
 
Induction of mutant A53T α-synuclein expression alters mitochondrial 
morphology 
The initial step in this investigation focused on determining what effect α-synuclein 
expression had upon mitochondrial morphology. Using polyclonal TOM20 antibody 
to label mitochondria, visualisation of the mitochondrial network within the cells 
displayed long interconnected organelles in empty vector cells (Figure 3A); the 
network extends throughout the length of the cell. These cells were also labelled with 
monoclonal α-synuclein antibody to ensure that no expression of the protein 
occurred. In mutant A53T α-synuclein-expressing cells, fragmentation of the 
mitochondrial network is visible from 24 hours post-induction with Ponasterone A 
(Figure 4). Un-induced A53T α-synuclein cells can be used as a comparison to 
demonstrate the specificity of protein expression following induction of protein 
expression, as no α-synuclein is detectable in these cells (Figure 3C). Induced 
mutant cells display evidence of fragmentation of the mitochondrial network after 72 
hours, apparent in cells with obvious α-synuclein expression and also in cells close 
by (Figure 3D). In the empty vector controls, the mitochondrial networks remain 
intact, in both the un-induced and induced groups, at all three investigated time 
points. Clarification of whether mitochondrial fragmentation increases in the induced 
x20 
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A53T α-synuclein group as time progresses has not been quantified, however 
qualitative observation would suggest that this is the case. 
 
Expression of A53T mutant α-synuclein protein has no effect on cellular 
respiratory capacity 
Analysis of cellular oxygen consumption rate as an indication of cellular respiratory 
capacity and mitochondrial function of the N27 cell lines using a Seahorse XFe 24 
analyser (Seahorse Bioscience) revealed no significant differences in the data from 
multiple experiments at two different time points post-induction of protein expression 
by Ponasterone A. When the data was analysed using a two way ANOVA (general  
 
Figure 3; Epifluorescence images captured on a Nikon 80i. (A)  Un-induced empty vector 
cells after 48 hours coverslip growth; long tubular mitochondrial networks are visible 
extending throughout the cells (B) Wild-type α-synuclein cells following 48 hour induction 
with Ponasterone A display similar expression levels to the mutant A53T cells (C) 
Uninduced A53T α-synuclein after 72 hours of growth; mitochondria display similar 
morphology to that of the empty vector cells, with long extension throughout the cell 
projections (D) Induced A53T α-synuclein cells 72 hours post-induction with Ponasterone A; 
fragmentation of mitochondrial and formation of punctate morphology is evident 
X40 
X40 
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Figure 4; A53T α-synuclein mutant N27 cells following 24 hours protein expression, induced by 
Ponasterone A. This confocal image allows differentiation between the labels, and the beginnings 
of mitochondrial fragmentation are visible in the TOM20-only panel. The high level of protein 
expression is clear and each cell is individually identifiable. 
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linear model) no significant variance is detectable in the respiratory capacity of the 
cells between the two time points, 24 and 48 hours (p=0.659), between the cell lines 
and treatment groups (p=0.080) or when all three factors are considered in relation 
to each other (p=0.802). These results indicate no change in the respiratory capacity 
of the cells in relation to expression of mutant α-synuclein protein, however the data 
is derived from only three individual experiments, which limits the strength of any 
conclusions; further work to clarify the accuracy of the results is required. Figure 5 
displays the mean respiratory capacity from three comparable experiments; an 
induced and non-induced group for both A53T α-synuclein mutant and empty vector 
cells provided a total of four treatment conditions for comparison in each of the tests. 
The differences in the respiratory capacity between the cell lines and treatments may 
be attributable to variance between the growth rates of the cells between the wells.  
Variance of wild type α-synuclein expression in a time course study 
Detection and comparison of α-synuclein using western blotting demonstrated that 
the level of protein increases the longer the cells are exposed to Ponasterone A in 
the media (Figure 6). Comparison of the 6 hour and 72 hour post-induction time 
points allows observation of a clear difference in protein levels. Alpha-synuclein is 
only present in the induced samples and the two positive controls; recombinant α-
synuclein and human brain sample. Β-actin is present in all of the samples, including 
the empty vector control and un-transfected N27 cells, which indicates that the lack 
of α-synuclein detected in these groups is due to a lack of expression, rather than as 
a failure to transfer protein in the analysis. Western blot results have only been 
generated for the wild-type α-synuclein samples, so further tests with mutant 
samples are required for comparison to the functional investigation. The results of 
Figure 5; Comparison of the cellular respiratory capacity of two cell types, each with an 
induced and non-induced group, at two time points over three experiments. (1,2) Cells 
treated with Ponasterone A for 24 hours prior to measurements of their oxygen 
consumption rate. (3) Cells treated with Ponasterone A for 48 hours prior to recording of 
their oxygen consumption rate. 
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this blot are promising and thus an increase in A53T α-synuclein expression over 
time is expected also.  
 
Discussion 
In this study, evidence of morphological changes in the mitochondrial network 
induced by mutant A53T α-synuclein is demonstrated, the effectiveness of this cell 
model is confirmed, as is its applicableness to multiple investigative methods. The 
necessity to fully optimise protocols when working with these cells using new 
techniques has been shown, and through further work it will be possible to extend 
this investigation to accurately determine the functional consequences of mutant 
protein expression. Once understanding of the proteins effects on mitochondria is 
confirmed, progression of the study to include approaches to neutralise or inhibit the 
effects of α-synuclein upon dopaminergic neuronal cells, providing a novel 
therapeutic target, may be possible. 
The immunocytochemistry and western blot results, whilst non-quantitative, 
suggest experimental provision of evidence showing the detrimental effect which 
mutant A53T α-synuclein has upon mitochondrial morphology, increasing the levels 
of network fragmentation as time, and subsequently protein levels, increase. A53T α-
synuclein expression leads to the fragmentation of normal long, tubular mitochondria 
and the formation of small, punctate mitochondria. In a 2012 study, Gui et al 
demonstrated how the induction of mitochondrial fragmentation is caused by α-
synuclein expression in mammalian cells, including neurons, which is concurrent 
Figure 6; Western blot film. Two negative and two positive controls were 
compared against the levels of α-synuclein at the 6 hour and 72 hour post-
induction time points. No α-synuclein is detected in either of the negative control 
groups, and strong signal is evident in the two positive controls. A clear difference 
in α-synuclein  is visible between the 6 hour and 72 hour time point, demonstrating 
that the level of protein expression increases with time following induction with 
Ponasterone A. [α-synuclein primary antibody – 1:1000 dilution, β-actin primary 
antibody – 1:10,000 dilution, Mouse secondary antibody – 1:10,000 dilution] 
Developed in ECL and exposed to nitrocellulose membrane for three minutes. 
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with our findings. The western blot data demonstrates an increase α-synuclein levels 
over time in the wild-type protein, but no data for the mutant protein has yet been 
obtained. The higher inducibility of the A53T cell line allows it to be suggested that a 
similar progression of protein accumulation would also occur in the mutant cells, 
however this requires confirmation. As the immunocytochemistry examined the effect 
of mutant A53T α-synuclein on the mitochondrial morphology of these dopaminergic 
neuronal cells, to establish whether the increased fragmentation over time is due to 
increased protein expression, western blots using mutant samples are required to 
confirm  that the fragmentation is time, and protein level, dependent. Evidence of 
increased expression of mutant A53T α-synuclein over time could also be beneficial 
in explaining functional analyses of mitochondrial function by tying these factors 
together so that a causal link may be further explored.  
Whilst the mechanism by which fragmentation of the mitochondrial network 
occurs has not been tested in this study, recent publications have demonstrated the 
ability of α-synuclein, both wild type and mutant forms, to translocate to the 
mitochondria where interactions with the outer membrane or alteration of the 
fission/fusion protein function may induce fragmentation (Kamp, 2010; Knott, 2008; 
Shavali, 2008; Sulzer, 2010). Interaction of α-synuclein with the outer mitochondrial 
membrane following specific translocation to that organelle is recurrent in the 
literature (Knott, 2008; Shavali, 2008), and specific membrane proteins which are 
highly expressed in mitochondrial membranes have been suggested as the target 
which drives this specific protein localisation (Nakamura, 2011). It has been 
proposed that a direct interaction between the protein and the mitochondrial 
membranes contribute to the mechanism through which the fragmentation is 
effected, in a Drp1-independent manner, as data suggested an absence of 
relationship between fission proteins and α-synuclein (Nakamura, 2011), however 
this is opposed by other work which ties fission/fusion protein interactions into the 
fragmentation process (Gui et al, 2012).   
Whilst no significance was recognised when considering the functional effects 
of α-synuclein on mitochondria, the results should not be discounted as useless. It 
may be that the data is unrepresentative, due to factors which were still being tested 
when the results were obtained, such as the best buffer to use, or the most 
appropriate oligomycin concentration, as the technique is new to these cells and 
alteration of an established method was required to create an illustrative study of 
mitochondrial function. As only two time points were considered, in three 
experiments, when testing mitochondrial function it is possible that the protein had 
not yet taken effect and repeating the experiment at a later time point could reveal 
the functional effects of α-synuclein expression in our cell model. In some studies, no 
change in mitochondrial function is detectable until the 48 hour time point, post-
induction/treatment with α-synuclein (Nakamura, 2011). Although functional 
impairment of mitochondria has been shown in studies using both wild type and 
mutant A53T α-synuclein (Devi, 2008; Kamp, 2010; Nakamura, 2011) others report 
differing findings; Orth et al (2003), Shavali et al (2008) and Wu et al (2009) all 
detected no direct influence of α-synuclein expression upon mitochondrial function, 
but detailed that the protein may still play a role in susceptibility to mitochondrial 
damage by enhancing the effect of known toxicants, such as MPTP and rotenone, to 
produce toxic effects at sub-toxic levels. Dauer et al (2002) produced similar results, 
establishing in an animal model that absence of α-synuclein provided resistance 
against the parkinsonian neurotoxin MPTP. The true effects of α-synuclein 
expression upon the functional capacity of mitochondria remains to be fully 
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corroborated, though it seems clear from our study, as well as in others, that any 
modifications of mitochondrial function occur after morphological changes have been 
induced (Nakamura, 2011). This may be due to functional complementation, in which 
the remaining healthy mitochondria within the cells may increase their activity to 
combat the loss of function in damaged organelles, which could delay the 
observation of respiratory dysfunction. Many studies link α-synuclein to mitochondrial 
complex 1 interactions and inhibition (Chinta et al, 2010; Devi et al, 2008; Loeb et al, 
2010) so perhaps more specific investigation of how the protein affects mitochondria 
would also be of value.  
In summary, this study successfully established the effect of A53T mutant α-
synuclein on the mitochondrial morphology of inducible dopaminergic neuronal cells, 
however further work is required to ascertain the role of this protein in alteration of 
cellular respiration and mitochondrial function. Additional work to optimise the 
method used for measuring mitochondrial function will benefit future investigation 
and provide more reliable results. Understanding of the mechanistic effects of α-
synuclein protein may lead on to targeting of these mechanisms in order to combat 
the progression and presentation of Parkinson’s disease. 
 
References 
 
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT 
(2001) Chronic systemic pesticide exposure reproduces features of Parkinson’s 
disease. Nature Neuroscience, 3; 1301-1306 
 
Campenhausen SV, Bornshien B, Wick R, Bötzel K, Sampaio C, Poewe W, Oertel 
W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson’s 
disease in Europe. European Neuropsychopharmacology, 15; 473-490  
 
Chan DC (2006) Dissecting mitochondrial fusion. Developmental cell, 11; 592-594 
 
Chen H and Chan DC (2009) Mitochondrial dynamics – fusion, fission, movement 
and mitophagy – in neurodegenerative diseases. Human Molecular Genetics, 18; 
169-176 
 
Chinta SJ, Mallajosyula JK, Rane A, Anderson JK (2010) Mitochondrial alpha-
synuclein accumulation impairs complex I function in dopaminergic neurons ___and 
results in increased mitophagy in vivo. Neuroscience Letters, 486; 235-239 
 
Cui M, Tang X, Christian WV,  Yoon Y, Tieu K (2010) Perturbations in mitochondrial 
dynamics induced by human mutant PINK1 can be rescued by the mitochondrial 
division inhibitor mdivi-1. The Journal of Biological Chemistry, 285; 11740-11752 
 
Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, 
Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski 
S, Burke R, Hen R (2002) Resistance of alpha-synuclein null mice to the 
parkinsonian neurotoxin MPTP. Proceedings of the National Academy of Sciences of 
the United States of America, 99; 14524-15429 
 
Dauer W and Przedborski S (2003) Parkinson’s disease: mechanisms and methods. 
Neuron, 39; 889-909 
The Plymouth Student Scientist, 2015, 8, (1), 4-19 
 
[17] 
 
 
Devi L, Raghavendra V, Prabhu BM, Avadhani NG, Anandatheeravarada HK (2008) 
Mitochondrial import and accumulation of alpha-synuclein impair complex 1 in 
human dopaminergic neuronal cultures and Parkinson disease brain. The Journal of 
Biological Chemistry, 283; 9089-9100 
 
Fornai F, Schlüter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti 
CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Südhof 
TC (2005) Parkinson-like syndrome induced by continuous MPTP infusion: 
convergent roles of ubiquitin-proteasome system and α-synuclein. Proceedings of 
the National Academy of Sciences of the United States of America, 102; 3413-3418 
 
Grayson M (2010) Parkinson’s Disease. Nature, 466 
 
Gui YX, Wang XY, Kang WY, Zhang YJ, Zhang Y, Zhou Y, Quinn TJ, Liu J, Chen SD 
(2012) Extracellular signal-regulated kinase is involved in alpha-synuclein-induced 
mitochondrial dynamic disorders by regulating dynamin-like protein 1. Neurobiology 
of Aging, 33; 2841-2854 
 
Ibánez P, Lasage S, Janin S, Lohmann E, Durif, Destée A, Bonnet AM, Brefel-
Coubon C, Heath S, Zelenoika D, Agid Y, Dürr A, Brice A (2009) α-synuclein gene 
rearrangements in dominantly inherited Parkinsonism: frequency, phenotype and 
mechanisms. Archives of Neurology, 66; 102-108 
 
Kamp F, Exner N, Lutz AK, Wender N, Hegermann J,_Brunner B, Nuscher B, Bartels 
T, Giese A, Beyer K, Einner S, Wiklhofer KF, Hasiss C (2010) Inhibition of 
mitochondrial fission by α-synuclein is rescued by PINK1, Parkin and DJ-1. The 
EMBO Journal, 29; 3571-3587 
 
Klein C and Westernberger A (2012) Genetics of Parkinson’s Disease. Cold Springs 
Harbour Laboratory Press, 2 
 
Knott A, Perkins G, Schwarzenbacher R, Bossy-Wetzel E (2008) Mitochondrial 
fragmentation in neurodegeneration. Nature Reviews Neuroscience, 9; 505-516 
 
Langston JW, Ballard P, Tetrad JW, Irwin I (1983) Chronic parkinsonism in humans 
due to a product of mereperidine-analog synthesis. Science, 25; 979-980 
 
Loeb V, Yakunin E, Saada A, Sharon R (2010) The transgenic overexpression of 
alpha-synuclein and not its related pathology associates with complex I inhibition. 
The Journal of Biological Chemistry, 285; 7334-7343 
 
Marieb EN and Hoene K (2010) Human Anatomy and Physiology, 8th Edition,  
Benjamin Cummings 
 
Mecusen S, DeVay R, Block J, Cassidy-Stone A, Wayson S, McCaffery JM, Numari 
J (2006) Mitochondrial inner-membrane fusion and crista maintenance requires the 
dynamin-related GTPase Mgm1. Cell, 127; 383-395 
 
The Plymouth Student Scientist, 2015, 8, (1), 4-19 
 
[18] 
 
Nakamura K, Nemani VM, Azarbal F, Sklbinski G, Levy JM, Egami K, Muniskina L, 
Zhang J, Garcher B, Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum 
RL, Masliah E, Edwards RH (2011) Direct membrane association drives 
mitochondrial fission by the Parkinson disease-associated protein α-synuclein. The 
Journal of Biological Chemistry, 286; 20710-20726 
 
Nunomura A, Perry G, Aliev G, Hirai K, Takada A, Balraj EK, Jones PK, Ghanbari H, 
Wataya T, Shimohama S, Chiba S, Atwood CS, Peterson RB, Smith MA (2001) 
Oxidative damage is the earliest event in Alzheimer’s disease. Journal of 
Neuropathology and Experimental Neurology, 60; 759-767 
 
Orth M, Tabrizi SJ, Schapira AHV, Cooper JM (2003) α-synuclein expression in 
Hek293 cells enhances the mitochondrial sensitivity to rotenone. Neuroscience 
Letters, 351; 29-32 
 
Polymeropoulos MH (1998) Autosomal dominant Parkinson’s disease and alpha-
synuclein. Annals of Neurology, 44; 63-64 
 
Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P (2004) Alpha-
synuclein and Parkinson’s disease. The Journal of the Federation of American 
Societies for Experimental Biology, 18; 617-626 
 
Schnabel J (2010) Secrets of the shaking palsy. Nature, 466 
 
Shavali S, Brown-Borg HM, Ebadi M, Porter J (2008) Mitochondrial localisation of 
alpha-synuclein protein in alpha-synuclein overexpressing cells. Neuroscience 
Letters, 439; 125-128 
 
Siegel GJ, Albers RW, Brady ST, Price DL (2006) Basic Neurochemistry; Molecular, 
Cellular and Medical Aspects, ELSEVIER 
 
Smith K (2010) Treatment Frontiers. Nature, 466 
 
Stephanis L (2012) α-synuclein in Parkinson’s Disease. Cold Springs Harbour 
Laboratory Press 
 
Sulzer D (2010) Clues to how alpha-synuclein damages neurons in Parkinson’s 
disease. Movement Disorders, 25; s27-s31 
 
Sum CH, Lio DSS, Mok SS, Masters CL, Hill AF, Culvenor JG, Cheng HC (2006) C-
terminal truncation and Parkinson’s disease-associated mutations down-regulate the 
protein serine/threonine kinase activity of PTEN-induced kinase-1. Human Molecular 
Genetics, 15; 3251-3262 
 
Valente EM, Abou-Sleiman PM, Caputo V, Muqit MMK, Harvey K, Gisport S, Ali Z, 
Turco DD, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-
Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, 
Dallapicolla B, Auburger G, Wood NW (2004) Hereditary Early-Onset Parkinson’s 
Disease Caused by Mutations in PINK1. Science, 304; 1158-1160 
 
The Plymouth Student Scientist, 2015, 8, (1), 4-19 
 
[19] 
 
Valente EM, Salvi S, Ialongo T, Marongui R, Elia AE, Caputo V, Romito L, Albanese 
A, Dallapiccola B, Bentivoglio AR (2004) PINK1 mutations are associated with 
sporadic early-onset Parkinsonism. Annals of Neurology, 56; 336-341 
 
Wild P and Dikic I (2010) Mitochondria get a Parkin’ ticket. Nature Cell Biology, 12; 
104-106 
 
Wu F, Poon WS, Lu G, Wang A, Meng H, Feng L, Li Z, Liu S (2009) α-synuclein 
knockdown attenuates MPP+-induced mitochondrial dysfunction of SHSY5Y cells. 
Brain Research, 1292; 173-179 
 
Xie W and Cheng KKK (2012) Alpha-synuclein impairs normal dynamics of 
mitochondria in cell and animal models of Parkinson’s disease. Journal of 
Neurochemistry, 122; 404-414 
 
Youle RJ and van der Bliek AM (2012) Mitochondrial fission, fusion and stress. 
Science, 337; 1062-1065 
 
 
